

7 August 2024

Enlitic® sells CXR Focal Opacity to Clairvo

Disposal of non-core technology enables Enlitic to focus its resources on strategic growth.

Highlights

- Enlitic and Clairvo have reached an agreement to sell CXR Focal Opacity to Clairvo for a cash consideration of US\$500,000
 - CXR Focal Opacity is a non-core capability owned by Enlitic which contains detection and triage algorithms relating to chest x-rays
 - CXR Focal Opacity was previously distributed by Clairvo in Japan on behalf of Enlitic
-

Enlitic, Inc. (ASX: ENL) (“Enlitic” or “the Company”), is pleased to announce it has reached an agreement to sell CXR Focal Opacity, Enlitic’s chest x-ray technology, to Clairvo Technologies, Inc (“Clairvo”) for a cash consideration of US\$500,000.

CXR Focal Opacity is a detection and triage technology which aids the detection of abnormalities in chest x-rays. As Enlitic’s growth strategy has evolved to focus on its core competencies in data standardisation, this technology has become non-core. Clairvo have previously distributed CXR Focal Opacity in Japan and remains a distributor of Enlitic’s core products in Japan.

Under the terms of the agreement, Enlitic assigns its right, title and interest in CXR Focal Opacity to Clairvo and also grants Clairvo perpetual non-exclusive licenses of certain patents relevant to CXR Focal Opacity and to certain Enlitic Background IP as needed by Clairvo to use and practice CXR Focal Opacity.

Clairvo is a wholly owned subsidiary of Marubeni Corporation, which holds approximately 12.3% of the shares in Enlitic at the date of this Announcement. Mr Riichi Yamada, a Non-Executive Director of Enlitic nominated by Marubeni Corporation, has not participated in any consideration or approval of the transaction or its terms in his capacity as a director of the Company.

– ENDS –

This announcement was authorised for release by the Board of Enlitic, Inc.

Enquiries

Enlitic Investor Relations

Australia:

invest_au@enlitic.com

USA:

invest@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that has the ability to improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.